Jyoti Kulkarni, MD
Family Medicine · O Fallon, MONPI 1649281668
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 175 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 18.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,389 and has fallen 82.3% since, to $245 in 2025.
Across 175 payments — averaging $17.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$572
- GSK$362
- Lilly USA, LLC$320
- Pfizer$293
- Novo Nordisk$264
- Boehringer Ingelheim$247
- plus $1K from 14 others
What the payments were for
- Food & beverage$3,103100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 25 | $572 |
| GSK | 23 | $362 |
| Lilly USA, LLC | 17 | $320 |
| Pfizer | 24 | $293 |
| Novo Nordisk | 15 | $264 |
| Boehringer Ingelheim | 12 | $247 |
| AstraZeneca | 8 | $182 |
| Amgen | 9 | $175 |
| Abbott | 10 | $159 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $110 |
| E.r. Squibb & Sons, L.L.C. | 7 | $110 |
| Exact Sciences | 5 | $79 |
| Axsome Therapeutics, Inc. | 2 | $43 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $42 |
| Sanofi-aventis U.S. LLC | 2 | $34 |
| Otsuka America Pharmaceutical, Inc. | 2 | $32 |
| Bayer | 2 | $31 |
| Johnson & Johnson | 1 | $22 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
How this compares
$3,103 in reported general payments places this provider in the 80th percentile of 2,203 family medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 100 | $99,410 |
| MounjaroTirzepatide | 70 | $77,553 |
| JardianceEmpagliflozin | 51 | $54,020 |
| OzempicSemaglutide | 45 | $48,129 |
| Breo ElliptaFluticasone/Vilanterol | 72 | $45,352 |
| FarxigaDapagliflozin Propanediol | 37 | $39,720 |
| XareltoRivaroxaban | 25 | $35,683 |
| JanuviaSitagliptin Phosphate | 37 | $32,267 |
| VraylarCariprazine Hcl | 15 | $31,736 |
| MyrbetriqMirabegron | 32 | $27,234 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 87 | $22,089 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 19 | $19,189 |
| VascepaIcosapent Ethyl | 23 | $18,340 |
| TrulicityDulaglutide | 14 | $17,590 |
| LinzessLinaclotide | 13 | $16,316 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $293 | $99,410100 claims |
| Lilly USA, LLCMounjaro, Trulicity | $320 | $95,14284 claims |
| GSKBreo Ellipta, Arexvy, Anoro Ellipta | $362 | $79,978175 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $247 | $73,20970 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $182 | $52,03352 claims |
| Novo NordiskOzempic | $264 | $48,12945 claims |
| AbbVieVraylar, Linzess | $572 | $48,05228 claims |
| Johnson & JohnsonXarelto | $22 | $35,68325 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,203 family medicine providers in Missouri.
Other family medicine in O Fallon
- Caitlin RogersO Fallon$20K
- Stephen AdamsSpringfield$636K
- Justin PuckettKirksville$568K
- Matthew BeckerditeOfallon$225K
- Roger CadySpringfield$175K
- James LasalleExcelsior Springs$130K
- Matthew TiefenbrunnSullivan$105K
- Ayobami OduwoleGrandview$92K
- Michael DonovanSaint Louis$78K
- Blair ThedingerKansas City$71K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.